These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22998042)

  • 41. Pharmacogenetics and psychopharmacotherapy.
    Poolsup N; Li Wan Po A; Knight TL
    J Clin Pharm Ther; 2000 Jun; 25(3):197-220. PubMed ID: 10886465
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolism of psychotropic drugs: pharmacological and clinical relevance.
    Daniel W
    Pol J Pharmacol; 1995; 47(5):367-79. PubMed ID: 8868127
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytochrome P450 polymorphisms and response to antipsychotic therapy.
    Scordo MG; Spina E
    Pharmacogenomics; 2002 Mar; 3(2):201-18. PubMed ID: 11972442
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Therapeutic drug monitoring in epileptology and psychiatry].
    Brandt C; Baumann P; Eckermann G; Hiemke C; May TW; Rambeck B; Pohlmann-Eden B
    Nervenarzt; 2008 Feb; 79(2):167-74. PubMed ID: 17701390
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Contribution of genotyping and phenotyping of biotransformation in therapeutic drug monitoring].
    Barré J
    Therapie; 2001; 56(3):251-5. PubMed ID: 11475803
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Therapeutic drug monitoring: A pharmacotherapeutic tool in psychiatry].
    Stephan PL; Etzensberger M; Jaquenoud Sirot E
    Praxis (Bern 1994); 2006 Apr; 95(17):671-8. PubMed ID: 16686323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of psychotropic drugs in special populations.
    Rudorfer MV
    J Clin Psychiatry; 1993 Sep; 54 Suppl():50-4; discussion 55-6. PubMed ID: 8407858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.
    Baumann P; Ulrich S; Eckermann G; Gerlach M; Kuss HJ; Laux G; Müller-Oerlinghausen B; Rao ML; Riederer P; Zernig G; Hiemke C;
    Dialogues Clin Neurosci; 2005; 7(3):231-47. PubMed ID: 16156382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.
    Frank D; Jaehde U; Fuhr U
    Eur J Clin Pharmacol; 2007 Apr; 63(4):321-33. PubMed ID: 17273835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CYP3A activity: towards dose adaptation to the individual.
    Hohmann N; Haefeli WE; Mikus G
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):479-97. PubMed ID: 26950050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacogenetics and psychoactive drug therapy: ready for the patient?
    Steimer W
    Ther Drug Monit; 2010 Aug; 32(4):381-6. PubMed ID: 20526233
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of probe drugs as predictors of drug metabolism in humans.
    Kivistö KT; Kroemer HK
    J Clin Pharmacol; 1997 Jan; 37(S1):40S-48S. PubMed ID: 9048284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Implementation of CYP2D6 genotyping in psychiatry.
    Loovers HM; van der Weide J
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1065-77. PubMed ID: 19572825
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping.
    de Leon J; Susce MT; Johnson M; Hardin M; Maw L; Shao A; Allen AC; Chiafari FA; Hillman G; Nikoloff DM
    CNS Spectr; 2009 Jan; 14(1):19-34. PubMed ID: 19169185
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians.
    Schoretsanitis G; Paulzen M; Unterecker S; Schwarz M; Conca A; Zernig G; Gründer G; Haen E; Baumann P; Bergemann N; Clement HW; Domschke K; Eckermann G; Egberts K; Gerlach M; Greiner C; Havemann-Reinecke U; Hefner G; Helmer R; Janssen G; Jaquenoud-Sirot E; Laux G; Messer T; Mössner R; Müller MJ; Pfuhlmann B; Riederer P; Saria A; Schoppek B; Silva Gracia M; Stegmann B; Steimer W; Stingl JC; Uhr M; Ulrich S; Waschgler R; Zurek G; Hiemke C
    World J Biol Psychiatry; 2018 Apr; 19(3):162-174. PubMed ID: 29493375
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.
    Tracy TS; Chaudhry AS; Prasad B; Thummel KE; Schuetz EG; Zhong XB; Tien YC; Jeong H; Pan X; Shireman LM; Tay-Sontheimer J; Lin YS
    Drug Metab Dispos; 2016 Mar; 44(3):343-51. PubMed ID: 26681736
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology.
    van der Weide J; Steijns LS
    Ann Clin Biochem; 1999 Nov; 36 ( Pt 6)():722-9. PubMed ID: 10586308
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Using pharmacogenomics and therapeutic drug monitoring to guide drug selection and dosing in outpatient mental health comprehensive medication management.
    Brown JT; Bishop JR; Schneiderhan ME
    Ment Health Clin; 2020 Jul; 10(4):254-258. PubMed ID: 32685338
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabolic drug interactions with new psychotropic agents.
    Spina E; Scordo MG; D'Arrigo C
    Fundam Clin Pharmacol; 2003 Oct; 17(5):517-38. PubMed ID: 14703714
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
    Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
    Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.